The SCOPE trial. Study on Cognition and Prognosis in the Elderly

Area of Science:

• Cardiology
• Geriatrics
• Pharmacology

Background:

• Elderly hypertension management requires outcome data for cardiovascular endpoints and cognitive function.
• Angiotensin receptor blockers are a key therapeutic class for hypertension.

Purpose of the Study:

• To evaluate the efficacy of candesartan versus placebo in reducing cardiovascular events and cognitive decline in elderly hypertensive patients.

Main Methods:

• The Study on Cognition and Prognosis in the Elderly (SCOPE) randomized 4500 elderly hypertensive patients.
• Patients received candesartan or placebo for 4.5 years, monitoring cardiovascular mortality, myocardial infarction, stroke, and cognitive function.

Main Results:

• Candesartan did not significantly reduce the primary endpoint of combined cardiovascular mortality, non-fatal myocardial infarction, and non-fatal stroke (RR 11%, p=0.19).
• No significant difference in cognitive function decline was observed between candesartan and placebo groups.
• Concomitant hydrochlorothiazide use in the placebo group reduced blood pressure differences, potentially impacting study power.

Conclusions:

• Candesartan did not demonstrate a significant benefit in reducing major cardiovascular events or preserving cognitive function in this elderly hypertensive population.
• Further research and subgroup analyses may be warranted to explore potential benefits of candesartan in specific patient groups.